These same companies that manufacture and distribute BPC-157 and bodybuilding drugs already also offer various GLP1 drugs, semaglutide, tirzepatide, retatrutide. Google around and you can find them available for much cheaper via grey market vendors.
So high semaglutide pricing won't end up "bankrupting" the US medical system. It'll push an ever larger number of patients -- and more than a few well-meaning doctors, who already recommend things like BPC-157 -- into the gray market. That this would further delegitimize the medical establishment and FDA would be a well-deserved outcome.